Novartis CEO Vas Narasimhan vows not to sell Sandoz generics unit Medical Dialogues Bureau29 July 2019 9:17 AM ISTNovartis is revamping Sandoz, a process Narasimhan has previously said will take roughly the next year and a half. He has already sold a generic U.S....
Novartis CEO sets aside 700 Million Dollar to settle doctor bribery lawsuit Medical Dialogues Bureau20 July 2019 9:52 AM ISTZURICH: Novartis Chief Executive Vas Narasimhan set aside $700 million to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close...
Alcon, Eye Care Unit of Novartis picks Geneva over Texas for new HQ Medical Dialogues Bureau13 Sept 2018 9:21 AM ISTZURICH: The headquarters of Alcon, the eye care unit of Novartis which will be spun off to shareholders in 2019, will move from the division's...
Novartis posts eye drug data amid play for Eylea's turf Ruby Khatun Khatun14 Nov 2017 9:45 AM ISTZURICH: Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new...
Novartis Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data Ruby Khatun Khatun21 Sept 2017 9:57 AM ISTBasel, September 13, 2017 - Novartis announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin...
Novartis hopeful for novel heart drug, despite modest benefit Ruby Khatun Khatun28 Aug 2017 1:05 PM ISTZURICH: Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection...
